Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker ATRA
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | ATRA Atara Biotherapeutics, Inc. | Steven A. Cohen | 687,718 | 7.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | ATRA Atara Biotherapeutics, Inc. | Point72 Capital Advisors, Inc. | 687,718 | 7.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | ATRA Atara Biotherapeutics, Inc. | Point72 Asset Management, L.P. | 687,718 | 7.6% | SCHEDULE 13G/A ↗ |
| Jul 24, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Redmile Strategic Long Only Trading Sub, Ltd. | 401,901 | 4.2% | SCHEDULE 13D/A ↗ |
| Jul 24, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Redmile Biopharma Investments II, L.P. | 631,020 | 6.6% | SCHEDULE 13D/A ↗ |
| Jul 24, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Jeremy Green | 950,994 | 9.9% | SCHEDULE 13D/A ↗ |
| Jul 24, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Redmile Group, LLC | 950,994 | 9.9% | SCHEDULE 13D/A ↗ |
| May 14, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Redmile Strategic Long Only Trading Sub, Ltd. | 576,148 | 6.1% | SCHEDULE 13D/A ↗ |
| May 14, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Redmile Biopharma Investments II, L.P. | 651,924 | 6.9% | SCHEDULE 13D/A ↗ |
| May 14, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Jeremy C. Green | 950,994 | 9.9% | SCHEDULE 13D/A ↗ |
| May 14, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Redmile Group, LLC | 950,994 | 9.9% | SCHEDULE 13D/A ↗ |
| May 13, 2026 | SCHEDULE 13G | ATRA Atara Biotherapeutics, Inc. | Phillip Gross | 700,000 | 8.6% | SCHEDULE 13G ↗ |
| May 13, 2026 | SCHEDULE 13G | ATRA Atara Biotherapeutics, Inc. | Robert Atchinson | 700,000 | 8.6% | SCHEDULE 13G ↗ |
| May 13, 2026 | SCHEDULE 13G | ATRA Atara Biotherapeutics, Inc. | Adage Capital Management, L.P. | 700,000 | 8.6% | SCHEDULE 13G ↗ |
| May 11, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | James Huang | 1.32M | 16.1% | SCHEDULE 13D/A ↗ |
| May 11, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Panacea Opportunity Fund I GP Company, Ltd. | 307,899 | 3.8% | SCHEDULE 13D/A ↗ |
| May 11, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Panacea Opportunity Fund I, L.P. | 307,899 | 3.8% | SCHEDULE 13D/A ↗ |
| May 11, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Panacea Venture Healthcare Fund II GP Company, Ltd. | 1.01M | 12.4% | SCHEDULE 13D/A ↗ |
| May 11, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Panacea Venture Healthcare Fund II, L.P. | 1.01M | 12.4% | SCHEDULE 13D/A ↗ |
| May 11, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Panacea Innovation Limited | 1.32M | 16.1% | SCHEDULE 13D/A ↗ |
| May 8, 2026 | SCHEDULE 13G | ATRA Atara Biotherapeutics, Inc. | Steven A. Cohen | 526,682 | 6.2% | SCHEDULE 13G ↗ |
| May 8, 2026 | SCHEDULE 13G | ATRA Atara Biotherapeutics, Inc. | Point72 Capital Advisors, Inc. | 526,682 | 6.2% | SCHEDULE 13G ↗ |
| May 8, 2026 | SCHEDULE 13G | ATRA Atara Biotherapeutics, Inc. | Point72 Asset Management, L.P. | 526,682 | 6.2% | SCHEDULE 13G ↗ |
| May 7, 2026 | SCHEDULE 13G/A (amended) | ATRA Atara Biotherapeutics, Inc. | EcoR1 Capital Fund Qualified, L.P. | 1.45M | 16.2% | SCHEDULE 13G/A ↗ |
| May 7, 2026 | SCHEDULE 13G/A (amended) | ATRA Atara Biotherapeutics, Inc. | Oleg Nodelman | 1.55M | 17.4% | SCHEDULE 13G/A ↗ |
| May 7, 2026 | SCHEDULE 13G/A (amended) | ATRA Atara Biotherapeutics, Inc. | EcoR1 Capital, LLC | 1.55M | 17.4% | SCHEDULE 13G/A ↗ |
| Jan 14, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | James Huang | 1.63M | 20.0% | SCHEDULE 13D/A ↗ |
| Jan 14, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Panacea Opportunity Fund I GP Company, Ltd. | 307,899 | 4.1% | SCHEDULE 13D/A ↗ |
| Jan 14, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Panacea Opportunity Fund I, L.P. | 307,899 | 4.1% | SCHEDULE 13D/A ↗ |
| Jan 14, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Panacea Venture Healthcare Fund II GP Company, Ltd. | 1.32M | 18.2% | SCHEDULE 13D/A ↗ |
| Jan 14, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Panacea Venture Healthcare Fund II, L.P. | 1.32M | 18.2% | SCHEDULE 13D/A ↗ |
| Jan 14, 2026 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Panacea Innovation Limited | 1.63M | 20.0% | SCHEDULE 13D/A ↗ |
| Nov 14, 2025 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Redmile Strategic Long Only Trading Sub, Ltd. | 376,377 | 5.0% | SCHEDULE 13D/A ↗ |
| Nov 14, 2025 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Redmile Biopharma Investments II, L.P. | 452,153 | 6.0% | SCHEDULE 13D/A ↗ |
| Nov 14, 2025 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | RedCo I, L.P. | 347,442 | 4.7% | SCHEDULE 13D/A ↗ |
| Nov 14, 2025 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Jeremy C. Green | 751,223 | 9.9% | SCHEDULE 13D/A ↗ |
| Nov 14, 2025 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Redmile Group, LLC | 751,223 | 9.9% | SCHEDULE 13D/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | ATRA Atara Biotherapeutics, Inc. | EcoR1 Capital Fund Qualified, L.P. | 667,639 | 9.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | ATRA Atara Biotherapeutics, Inc. | Oleg Nodelman | 715,853 | 9.9% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | ATRA Atara Biotherapeutics, Inc. | EcoR1 Capital, LLC | 715,853 | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 19, 2025 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | James Huang | 1.71M | 20.0% | SCHEDULE 13D/A ↗ |
| Aug 19, 2025 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Panacea Opportunity Fund I GP Company, Ltd. | 307,900 | 4.2% | SCHEDULE 13D/A ↗ |
| Aug 19, 2025 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Panacea Opportunity Fund I, L.P. | 307,900 | 4.2% | SCHEDULE 13D/A ↗ |
| Aug 19, 2025 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Panacea Venture Healthcare Fund II GP Company, Ltd. | 1.41M | 20.0% | SCHEDULE 13D/A ↗ |
| Aug 19, 2025 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Panacea Venture Healthcare Fund II, L.P. | 1.41M | 20.0% | SCHEDULE 13D/A ↗ |
| Aug 19, 2025 | SCHEDULE 13D/A (amended) | ATRA Atara Biotherapeutics, Inc. | Panacea Innovation Limited | 1.71M | 20.0% | SCHEDULE 13D/A ↗ |
| May 23, 2025 | SCHEDULE 13D | ATRA Atara Biotherapeutics, Inc. | Redmile Biopharma Investments II, L.P. | 406,137 | 5.8% | SCHEDULE 13D ↗ |
| May 23, 2025 | SCHEDULE 13D | ATRA Atara Biotherapeutics, Inc. | RedCo I, L.P. | 347,442 | 5.0% | SCHEDULE 13D ↗ |
| May 23, 2025 | SCHEDULE 13D | ATRA Atara Biotherapeutics, Inc. | Jeremy C. Green | 705,207 | 9.9% | SCHEDULE 13D ↗ |
| May 23, 2025 | SCHEDULE 13D | ATRA Atara Biotherapeutics, Inc. | Redmile Group, LLC | 705,207 | 9.9% | SCHEDULE 13D ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:55 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances